<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152514</url>
  </required_header>
  <id_info>
    <org_study_id>Epimorph for VATS</org_study_id>
    <nct_id>NCT02152514</nct_id>
  </id_info>
  <brief_title>RCT Comparing Analgesia Post-VATS With Epimorph VS Placebo</brief_title>
  <official_title>Randomized Controlled Trial Comparing Post-VATS Analgesia Between Patients With an Intrathecal Injection of Morphine and Sufentanil Versus Placebo.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if the administration of a mix of Sufentanil and
      Morphine in intrathecal is a better analgesia regimen than PCA alone in patient post-VATS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the need for analgesia (Hydromorphone PCA) of two groups of patients
      post-VATS. The placebo group will only have a PCA for post-operative analgesia, witch is the
      standard care for patient post-VATS. The experimental group will have a intrathecal injection
      of a mix of morphine and sufentanil before the induction of anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to technical details recruitment was unreasonably slow
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hydromorphone consommation</measure>
    <time_frame>24hr</time_frame>
    <description>The amount of Hydromorphone needed by the patient in the first 24hr after his VATS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Every 4h x 24hr</time_frame>
    <description>A VAS will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of narcotics</measure>
    <time_frame>Every 4h x 24hr</time_frame>
    <description>Including :
Saturation [Saturation (%) and the need for oxygen (l/min) will be assess to evaluate the incidence of desaturation and hypoventilation in both arms]
Sedation [Sedation will be evaluate with the Riker Sedation Agitation Scale]
Respiratory rate [To evaluate the incidence of hypoventilation (&lt;8/min) and to compare the average between both arms]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions associate with rachianesthesia</measure>
    <time_frame>24hr</time_frame>
    <description>Including :
Backache
Headache
Legs strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions of narcotics</measure>
    <time_frame>24hr</time_frame>
    <description>Including :
Nausea
Pruritis
Urinary retention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Thoracic Surgery, Video-assisted</condition>
  <condition>Postoperative Pain</condition>
  <condition>Rachianesthesia</condition>
  <condition>Sufentanil</condition>
  <condition>Morphine</condition>
  <arm_group>
    <arm_group_label>Intrathecal Morphine/Sufentanil and PCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will have a PCA for analgesia rescue in the post-operative period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCA alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will NOT receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will only have a PCA for analgesia in the post-operative period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal Morphine/Sufentanil</intervention_name>
    <arm_group_label>Intrathecal Morphine/Sufentanil and PCA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCA</intervention_name>
    <arm_group_label>Intrathecal Morphine/Sufentanil and PCA</arm_group_label>
    <arm_group_label>PCA alone</arm_group_label>
    <other_name>Patient Controlled Analgesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  VATS

          -  ASA 1,2 or 3

          -  Minimum weight of 50 kg

          -  Patient able to consent

        Exclusion Criteria:

          -  Patient refusal

          -  Patient unable to understand PCA

          -  Contraindication to rachianalgesia

          -  Zona

          -  Pregnancy

          -  Over 30 mg of morphine during the last 24 hours

          -  Use of Pregabalin, Gabapentin, Doluxetin, Amitriptyline or NSAI in a context of
             chronic pain

          -  Severe allergic reaction to morphine, hydromorphone, sufentanil or local anesthetic

          -  Intubation over 1 hour after surgery (unability to use PCA)

          -  High risk of conversion to thoracotomy

          -  Unable to perform rachianalgesia due to technical difficulties
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanick Sansoucy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>January 18, 2016</last_update_submitted>
  <last_update_submitted_qc>January 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Yanick Sansoucy</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

